What is Collegium Pharmaceutical Enterprise Value?
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Collegium Pharmaceutical's Enterprise Value is $1,397.1 Mil.
Collegium Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $209.2 Mil. Therefore, Collegium Pharmaceutical's EV-to-EBIT ratio for today is 6.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Collegium Pharmaceutical's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Enterprise Value falls into.
Collegium Pharmaceutical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Collegium Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (NAS:COLL) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Collegium Pharmaceutical's EV-to-EBIT for today is
Collegium Pharmaceutical's current Enterprise Value is $1,397.1 Mil.
Collegium Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $209.2 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Collegium Pharmaceutical's EV-to-EBITDA for today is:
Collegium Pharmaceutical's current Enterprise Value is $1,397.1 Mil.
Collegium Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $355.6 Mil.
Collegium Pharmaceutical's current Enterprise Value is $1,397.1 Mil.
Collegium Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $566.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical Enterprise Value Related Terms
Thank you for viewing the detailed overview of Collegium Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Collegium Pharmaceutical (Collegium Pharmaceutical) Business Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COLL has been successfully added to your 